Welcome to Francis Academic Press

Academic Journal of Humanities & Social Sciences, 2020, 3(1); doi: 10.25236/AJHSS.2020.030111.

Advances in the study of hyperuricemia and chronic kidney disease


Yunli Gui, Xiaorong Bao*

Corresponding Author:
Xiaorong Bao

Jinshan Hospital of Fudan University, Shanghai 201508, China.
*Corresponding author e-mail:wangyu-syd@sina.com


At present, hyperuricemia is becoming an increasingly serious problem after hypertension, hyperglycemia, and hyperlipidemia. It has also become a hot topic in recent years. Uric acid passes through the glomerular filtration and is then reabsorbed or excreted by the URAT1 transporter in the renal tubules. Hyperuricemia affects the functional status of the glomerulus and renal tubules, and high uric acid indirectly leads to renal insufficiency through vascular sclerosis. This article reviews the development of chronic kidney disease caused by high uric acid, including glomerular damage, renal tubule damage and vascular sclerosis.


Uric acid, Hyperuricemia, Chronic kidney disease, Renal tubule, Glomerular, Vascular sclerosis.

Cite This Paper

Yunli Gui, Xiaorong Bao. Advances in the study of hyperuricemia and chronic kidney disease. Academic Journal of Humanities & Social Sciences (2020) Vol. 3, Issue 1: 98-103. https://doi.org/10.25236/AJHSS.2020.030111.


[1] He J, Shlipak M, Anderson A, et al. Risk factors for heart failure in patients with chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) study [J]. Journal of the American Heart Association, 2017, 6(5): e005336.
[2] Jalal D I. Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review [J]. Current medical research and opinion, 2016, 32(11): 1863-1869.
[3] Hediger M A. Kidney function: gateway to a long life? [J]. Nature, 2002, 417(6887): 393.
[4] He J, Shlipak M, Anderson A, et al. Risk factors for heart failure in patients with chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) study [J]. Journal of the American Heart Association, 2017, 6(5): e005336.
[5] Solomon D H, Glynn R J, MacFadyen J G, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial [J]. Annals of internal medicine, 2018, 169(8): 535-542.
[6] Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate–anion exchanger that regulates blood urate levels [J]. Nature, 2002, 417(6887): 447.
[7] Tan P K, Liu S, Gunic E, et al. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout [J]. Scientific reports, 2017, 7(1): 665.
[8] Li Z, Sheng Y, Liu C, et al. Nox4 has a crucial role in uric acid induced oxidative stress and apoptosis in renal tubular cells [J]. Molecular medicine reports, 2016, 13(5): 4343-4348.
[9] Xiao J, Zhang X, Fu C, et al. Impaired Na+− K+-ATPase signaling in renal proximal tubule contributes to hyperuricemia-induced renal tubular injury [J]. Experimental & molecular medicine, 2018, 50(3): e452.
[10] Verzola D, Ratto E, Villaggio B, et al. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4 [J]. PloS one, 2014, 9(12): e115210.
[11] Obermayr R P, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease [J]. Journal of the American Society of Nephrology, 2008, 19(12): 2407-2413.
[12] Convento M S, Pessoa E, Dalboni M A, et al. Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage [J]. Urological research, 2011, 39(1): 21-27.
[13] Nakagawa T, Mazzali M, Kang D H, et al. Hyperuricemia causes glomerular hypertrophy in the rat [J]. American journal of nephrology, 2003, 23(1): 2-7.
[14] Fogo A B. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases [J]. Kidney international, 2000, 57: S15-S21.
[15] Gonick H C, RUBINI M E, GLEASON I O, et al. The renal lesion in gout [J]. Annals of internal medicine, 1965, 62(4): 667-674.
[16] Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis [J]. Renal failure, 2018, 40(1): 289-297.
[17] Cianciolo G, Donati G, La G M, et al. The cardiovascular burden of end-stage renal disease patients[J]. Minerva urologica e nefrologica= The Italian journal of urology and nephrology, 2010, 62(1): 51-66.
[18] Jansen K, Van Der Steen A F W, van Beusekom H M M, et al. Intravascular photoacoustic imaging of human coronary atherosclerosis [J]. Optics letters, 2011, 36(5): 597-599.
[19] Iyemere V P, Proudfoot D, Weissberg P L, et al. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification [J]. Journal of internal medicine, 2006, 260(3): 192-210.
[20] Schlieper G, Schurgers L, Brandenburg V, et al. Vascular calcification in chronic kidney disease: an update[J]. Nephrology Dialysis Transplantation, 2015, 31(1): 31-39.
[21] Mehta T, Nuccio E, McFann K, et al. Association of uric acid with vascular stiffness in the Framingham Heart Study [J]. American journal of hypertension, 2014, 28(7): 877-883.
[22] Kang D H, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease [J]. Journal of the American Society of Nephrology, 2002, 13(12): 2888-2897.
[23] Aroor A R, Jia G, Habibi J, et al. Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice [J]. Metabolism, 2017, 74: 32-40.
[24] Sedaghat S, Mattace-Raso F U S, Hoorn E J, et al. Arterial stiffness and decline in kidney function [J]. Clinical Journal of the American Society of Nephrology, 2015, 10(12): 2190-2197.
[25] Johnson R J, Feig D I, Herrera-Acosta J, et al. Resurrection of uric acid as a causal risk factor in essential hypertension [J]. 2005.